ResearcherSanta Monica CollegeActive in the last 2 years
Erlinda Maria Gordon
Matched on ORCID iD 0000-0003-2599-7188; OpenAlex author ID A5018623286. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper
Papers 4
- Treatment of Elderly Patients with Advanced Pancreatic Ductal Adenocarcinoma Utilizing a Metronomic Dose and Schedule of Chemotherapy: A Better Approach Last author DOI 10.20944/preprints202510.0364.v1↗
- Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and… Last author DOI 10.3389/fmmed.2022.1092286↗
- Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with De… Last author DOI 10.3892/mco.2021.2348↗
- A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Last author DOI 10.1016/j.omto.2018.12.005↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Sant P. Chawla · 3 shared papers, 2019–2022 · strength 0.42
- Paper Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinom… DOI 10.3892/mco.2021.2348↗
- Paper Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancrea… DOI 10.3389/fmmed.2022.1092286↗
- Paper A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanc… DOI 10.1016/j.omto.2018.12.005↗
- William H. Isacoff · 1 shared paper, 2025 · strength 0.28
- Howard W. Bruckner · 2 shared papers, 2019–2021 · strength 0.27
- Paper Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinom… DOI 10.3892/mco.2021.2348↗
- Paper A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanc… DOI 10.1016/j.omto.2018.12.005↗
- Michael Andrew Morse · 2 shared papers, 2019–2021 · strength 0.27
- Paper Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinom… DOI 10.3892/mco.2021.2348↗
- Paper A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanc… DOI 10.1016/j.omto.2018.12.005↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.